Education
About Us
Working with TipRanks
Follow Us
Illumina (IT:1ILMN)
:1ILMN
1ILMN Stock Chart & Stats
€106.76
€0.30(0.22%)
At close: 4:00 PM EST
€106.76
€0.30(0.22%)
Day’s Range― - ―
52-Week Range€61.00 - €145.14
Previous CloseN/A
Volume0.00
Average Volume (3M)22.00
Market Cap
$15.54B
Enterprise Value€15.42B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)25.9
Beta0.60
Next Earnings
Feb 05, 2026EPS Estimate
1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.16
Shares Outstanding152,800,000
10 Day Avg. Volume33
30 Day Avg. Volume22
Financial Highlights & Ratios
PEG Ratio-3.75
Price to Book (P/B)8.95
Price to Sales (P/S)4.86
P/FCF Ratio29.95
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue4.84
Enterprise Value/Gross Profit7.31
Enterprise Value/Ebitda15.62
Forecast
1Y Price Target
$100.08Price Target Upside-6.26% Downside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial OutlookIllumina raised operating margin and EPS guidance to reflect Q3 outperformance and change in China revenue expectation.
Market PerformanceIllumina stock rose 25% following their 3Q print, reflecting positive investor sentiment.
Revenue GrowthIllumina's clinical consumables revenue continued to accelerate, increasing to +12% year-over-year as clinical customers transition to the NovaSeq X.
Bears Say
Backlog And Revenue ConversionOnly 77% of the current backlog is expected to convert to revenue in the next 12 months, which is the lowest level since 2020.
Competitive ChallengesAnalysts maintain an Underperform rating for Illumina, citing structural, competitive, and market challenges.
Market CompetitionThe company's management is underestimating the competitive threat, particularly from competitors like Roche/Axelios, which could impact future performance.
Illumina News
1ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €61.00 and its highest was €145.14 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $15.54B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 05, 2026 which is in 91 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 30, 2025. The company reported €1.165 earnings per share for the quarter, beating the consensus estimate of €1.015 by €0.149.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.04.
How many shares outstanding does Illumina have?
Illumina has 152,800,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.165 in its last earnings report, beating expectations of €1.015. Following the earnings report the stock price went up 23.392%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in IT:1ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$100.08 (-6.26% Downside)
$100.08 (-6.26% Downside)
Blogger Sentiment
Bullish
IT:1ILMN Sentiment 80%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.86%
12-Months-Change
Fundamentals
Return on Equity
31.20%
Trailing 12-Months
Asset Growth
2.71%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
1ILMN Company Deck
1ILMN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical markets and the NovaSeq X transition, with revenue and earnings exceeding expectations. However, challenges in research markets and ongoing issues in China present hurdles. Despite these challenges, the company remains optimistic about its strategic initiatives and future growth.View all IT:1ILMN earnings summaries1ILMN Revenue Breakdown
72.16% Consumables
16.38% Service and other revenue
11.46% Instruments
1ILMN Stock 12 Month Forecast
Average Price Target
€100.08
▼(-6.26% Downside)
Technical Analysis
Options Prices
Currently, No data available
---